234 related articles for article (PubMed ID: 21872957)
1. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.
Hendrickson K; Phillips M; Smith W; Peterson L; Krohn K; Rajendran J
Radiother Oncol; 2011 Dec; 101(3):369-75. PubMed ID: 21872957
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
3.
Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
[TBL] [Abstract][Full Text] [Related]
4. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.
Lin Z; Mechalakos J; Nehmeh S; Schoder H; Lee N; Humm J; Ling CC
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1219-28. PubMed ID: 18313529
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.
Henriques de Figueiredo B; Zacharatou C; Galland-Girodet S; Benech J; De Clermont-Gallerande H; Lamare F; Hatt M; Digue L; De Mones del Pujol E; Fernandez P
Strahlenther Onkol; 2015 Mar; 191(3):217-24. PubMed ID: 25245468
[TBL] [Abstract][Full Text] [Related]
7. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.
Yasuda K; Onimaru R; Okamoto S; Shiga T; Katoh N; Tsuchiya K; Suzuki R; Takeuchi W; Kuge Y; Tamaki N; Shirato H
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):142-7. PubMed ID: 22583608
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry study of
Li H; Xu D; Han X; Ruan Q; Zhang X; Mi Y; Dong M; Guo S; Lin Y; Wang B; Li G
Clin Transl Oncol; 2018 Oct; 20(10):1329-1336. PubMed ID: 29623584
[TBL] [Abstract][Full Text] [Related]
9. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
10. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer.
Choi W; Lee SW; Park SH; Ryu JS; Oh SJ; Im KC; Choi EK; Kim JH; Jung SH; Kim S; Ahn SD
Radiother Oncol; 2010 Nov; 97(2):176-82. PubMed ID: 20855118
[TBL] [Abstract][Full Text] [Related]
11. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
12. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
15. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
16. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia dose painting by numbers: a planning study.
Thorwarth D; Eschmann SM; Paulsen F; Alber M
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):291-300. PubMed ID: 17448882
[TBL] [Abstract][Full Text] [Related]
18. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
19. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic
Thorwarth D; Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D
J Nucl Med; 2019 Dec; 60(12):1698-1704. PubMed ID: 31076504
[TBL] [Abstract][Full Text] [Related]
20. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
Askoxylakis V; Dinkel J; Eichinger M; Stieltjes B; Sommer G; Strauss LG; Dimitrakopoulou-Strauss A; Kopp-Schneider A; Haberkorn U; Huber PE; Bischof M; Debus J; Thieke C
Radiat Oncol; 2012 Sep; 7():157. PubMed ID: 22974533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
